[Role of genetic markers in personalization of anti-angiogenic therapy in patients with exudative age-related macular degeneration]. / Rol' geneticheskikh markerov v personalizatsii antiangiogennoi terapii ékssudativnoi formy vozrastnoi makuliarnoi degeneratsii.

The review presents data of clinical and pharmacogenetic research by Russian and foreign authors conducted within the last three years on the effectiveness of anti-angiogenic treatment against wet age-related macular degeneration (AMD). Scientific results on the association between angiogenesis-related gene polymorphisms responsible for predisposition to AMD on the one hand and a positive response to anti-VEGF therapy on the other are presented. Particular attention is paid to the main regulator of angiogenesis - the VEGF-A gene.